Physician profile
Steven Walsh
NPI 1013032572
$1,576.54
in general payments reported to CMS, 2019-2025
9 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $248 · 2021: $96.16 · 2022: $196 · 2023: $195 · 2024: $174 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $636.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $450.58 | 2019-2021 | |
| Coopervision INC. | $291.39 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Lombart Brothers, INC. | $268.60 | 2019-2025 | Opd-III |
| Bausch & Lomb Americas INC. | $216.34 | 2022-2025 | Infuse |
| Alcon Vision LLC | $185.12 | 2021-2024 | Total30, Clareon |
| Abb Con-Cise Optical Group LLC | $104.40 | 2019-2025 | Contact Lens, Spectacle Lenses |
| Abbvie INC. | $25.50 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.49 | 2020 | |
| Thea Pharma INC. | $17.12 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.